These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 29353875)

  • 21. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.
    Sharma P; Boyers D; Boachie C; Stewart F; Miedzybrodzka Z; Simpson W; Kilonzo M; McNamee P; Mowatt G
    Health Technol Assess; 2012; 16(17):1-266. PubMed ID: 22469073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effectiveness of next generation genomic sequencing for disease diagnosis: design of a randomized controlled trial in patients with colorectal cancer/polyposis syndromes.
    Gallego CJ; Bennette CS; Heagerty P; Comstock B; Horike-Pyne M; Hisama F; Amendola LM; Bennett RL; Dorschner MO; Tarczy-Hornoch P; Grady WM; Fullerton SM; Trinidad SB; Regier DA; Nickerson DA; Burke W; Patrick DL; Jarvik GP; Veenstra DL
    Contemp Clin Trials; 2014 Sep; 39(1):1-8. PubMed ID: 24997220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of the whole mitochondrial genome: translation of the Ion Torrent Personal Genome Machine system to the diagnostic bench?
    Seneca S; Vancampenhout K; Van Coster R; Smet J; Lissens W; Vanlander A; De Paepe B; Jonckheere A; Stouffs K; De Meirleir L
    Eur J Hum Genet; 2015 Jan; 23(1):41-8. PubMed ID: 24667782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Do health professionals value genomic testing? A discrete choice experiment in inherited cardiovascular disease.
    Buchanan J; Blair E; Thomson KL; Ormondroyd E; Watkins H; Taylor JC; Wordsworth S
    Eur J Hum Genet; 2019 Nov; 27(11):1639-1648. PubMed ID: 31186546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation for Genetic Disorders in the Absence of a Clinical Indication for Testing: Elective Genomic Testing.
    Lu JT; Ferber M; Hagenkord J; Levin E; South S; Kang HP; Strong KA; Bick DP
    J Mol Diagn; 2019 Jan; 21(1):3-12. PubMed ID: 30453057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Key emerging themes for assessing the cost-effectiveness of reporting incidental findings.
    Phillips KA; Ladabaum U; Pletcher MJ; Marshall DA; Douglas MP
    Genet Med; 2015 Apr; 17(4):314-5. PubMed ID: 25835195
    [No Abstract]   [Full Text] [Related]  

  • 27. Controversy and debate on clinical genomics sequencing-paper 1: genomics is not exceptional: rigorous evaluations are necessary for clinical applications of genomic sequencing.
    Wilson BJ; Miller FA; Rousseau F
    J Clin Epidemiol; 2017 Dec; 92():4-6. PubMed ID: 28870871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost Effectiveness of Karyotyping, Chromosomal Microarray Analysis, and Targeted Next-Generation Sequencing of Patients with Unexplained Global Developmental Delay or Intellectual Disability.
    Li Y; Anderson LA; Ginns EI; Devlin JJ
    Mol Diagn Ther; 2018 Feb; 22(1):129-138. PubMed ID: 29209992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exome sequencing: the expert view.
    Biesecker LG; Shianna KV; Mullikin JC
    Genome Biol; 2011 Sep; 12(9):128. PubMed ID: 21920051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical utility gene card for: Non-Syndromic Microphthalmia Including Next-Generation Sequencing-Based Approaches.
    Richardson R; Sowden J; Gerth-Kahlert C; Moore AT; Moosajee M
    Eur J Hum Genet; 2017 Apr; 25(4):. PubMed ID: 28098148
    [No Abstract]   [Full Text] [Related]  

  • 31. Lake Louise mutation detection meeting 2013: clinical translation of next-generation sequencing requires optimization of workflows and interpretation of variants.
    Smith A; Boycott KM; Jarinova O
    Hum Mutat; 2014 Feb; 35(2):265-9. PubMed ID: 24282140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-minimization analysis of sequential genetic testing versus targeted next-generation sequencing gene panels in patients with pheochromocytoma and paraganglioma.
    Pipitprapat W; Pattanaprateep O; Iemwimangsa N; Sensorn I; Panthan B; Jiaranai P; Chantratita W; Sorapipatcharoen K; Poomthavorn P; Mahachoklertwattana P; Sura T; Tunteeratum A; Srichan K; Sriphrapradang C
    Ann Med; 2021 Dec; 53(1):1244-1256. PubMed ID: 34309460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Challenges in the diagnosis and discovery of rare genetic disorders using contemporary sequencing technologies.
    Seaby EG; Ennis S
    Brief Funct Genomics; 2020 Jul; 19(4):243-258. PubMed ID: 32393978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A practical guide to genetic testing in endocrinology.
    Izatt L; Owens MM; Pierce H; Wilcox S; Park SM
    Clin Endocrinol (Oxf); 2022 Oct; 97(4):388-399. PubMed ID: 34528717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine.
    Hatanaka Y; Kuwata T; Morii E; Kanai Y; Ichikawa H; Kubo T; Hatanaka KC; Sakai K; Nishio K; Fujii S; Okamoto W; Yoshino T; Ochiai A; Oda Y
    Pathol Int; 2021 Nov; 71(11):725-740. PubMed ID: 34614280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDA-approved Next-Generation sequencing system could expand clinical genomic testing: experts predict MiSeqDx system will make genetic testing more affordable for smaller labs.
    Am J Med Genet A; 2014 Mar; 164A(3):x-xi. PubMed ID: 24591037
    [No Abstract]   [Full Text] [Related]  

  • 37. Translating genomics in cancer care.
    Bombard Y; Bach PB; Offit K
    J Natl Compr Canc Netw; 2013 Nov; 11(11):1343-53. PubMed ID: 24225968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consideration for Employer-Based and Geographic Attributes Included in Value Assessment Methods of Next-Generation Sequencing Tests.
    Hart MR; Spencer SJ
    J Manag Care Spec Pharm; 2019 Aug; 25(8):936-940. PubMed ID: 31347979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequencing-based diagnostics for pediatric genetic diseases: progress and potential.
    Abou Tayoun AN; Krock B; Spinner NB
    Expert Rev Mol Diagn; 2016 Sep; 16(9):987-99. PubMed ID: 27388938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determining Cost-Optimal Next-Generation Sequencing Panels for Rare Disease and Pharmacogenomics Testing.
    Katragadda S; Hall TO; Bettadapura R; Dalton JC; Ganapathy A; Ghana P; Hariharan R; Janakiraman A; Kotha KBVSSP; Manjunath A; Mannan AU; Ms N; Saraf S; Tzeng KTH; Veeramachaneni V
    Clin Chem; 2021 Aug; 67(8):1122-1132. PubMed ID: 34120169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.